ClinicalTrialsFinder
RecruitingPhase 2NCT05933239

Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients

A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)

Sponsor

Universitair Ziekenhuis Brussel

Enrollment

20 participants

Start Date

Mar 30, 2023

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new imaging agent called Ga-MMR-VHH2 in people with lung cancer. This radioactive tracer is designed to highlight certain immune cells (called macrophages) inside tumors when viewed on a PET scan. Researchers want to see if this can improve understanding of how the immune system responds to lung cancer. **You may be eligible if...** - You are 18 or older and have given informed consent - You have non-small cell lung cancer (local, locally advanced, or metastatic) - You are scheduled for surgery or a biopsy on at least one tumor - Your tumor is large enough to be measured (at least 10 mm) **You may NOT be eligible if...** - You have a poor performance status (very limited ability to carry out daily activities) - You are pregnant or breastfeeding - You have other conditions that would interfere with the imaging or study safety Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68GaNOTA-Anti-MMR-VHH2

Injection of the radiopharmaceutical and PET/CT imaging

Locations(1)

Universitair Ziekenhuis Brussel

Jette, Brussels Capital, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05933239

Related Trials

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

NCT074137571 location

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533283 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540346 locations

An External Control Arm Study in Non-Small Cell Lung Cancer

NCT071743888 locations